Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection
1 other identifier
observational
728
1 country
1
Brief Summary
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 26, 2020
CompletedStudy Start
First participant enrolled
March 26, 2020
CompletedFirst Posted
Study publicly available on registry
March 31, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 25, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 25, 2022
CompletedNovember 3, 2022
November 1, 2022
2 years
March 26, 2020
November 2, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
All-cause mortality
mortality of any cause
During 1 year follow-up
Secondary Outcomes (2)
30-day mortality
Within 30 days after inclusion
Major adverse cardiovascular events
During 1 year follow-up
Interventions
At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
Eligibility Criteria
The registry will include consecutive patients, tested for suspected SARS-CoV2/Covid-19 infection at the University Hospital Essen
You may qualify if:
- Patients with suspected SARS-CoV2/Covid-19 infection
You may not qualify if:
- Unwillingness to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Essen
Essen, North Rhine-Westphalia, 45147, Germany
Related Publications (1)
Mahabadi AA, Mincu R, Dykun I, Michel L, Kung A, Witzke O, Kill C, Buer J, Rassaf T, Totzeck M. Frequency and prognosis of CVD and myocardial injury in patients presenting with suspected COVID-19 - The CoV-COR registry. Int J Cardiol Heart Vasc. 2023 Apr;45:101184. doi: 10.1016/j.ijcha.2023.101184. Epub 2023 Feb 6.
PMID: 36776683DERIVED
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Tienush Rassaf, MD
University Hospital Essen, Deparment of Cardiology and Vascular Medicine
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 26, 2020
First Posted
March 31, 2020
Study Start
March 26, 2020
Primary Completion
March 25, 2022
Study Completion
July 25, 2022
Last Updated
November 3, 2022
Record last verified: 2022-11
Data Sharing
- IPD Sharing
- Will not share
Will be made available upon request